

HB1779



102ND GENERAL ASSEMBLY

State of Illinois

2021 and 2022

HB1779

Introduced 2/17/2021, by Rep. Mary E. Flowers

SYNOPSIS AS INTRODUCED:

215 ILCS 5/356z.43 new

Amends the Illinois Insurance Code to provide that an individual or group health care service plan contract that is issued, amended, delivered, or renewed on or after January 1, 2022 shall not require prior authorization for biomarker testing for an insured with advanced or metastatic stage 3 or 4 cancer, nor shall prior authorization be required for biomarker testing of cancer progression or recurrence in the insured with advanced or metastatic stage 3 or 4 cancer. Defines "biomarker testing".

LRB102 10161 BMS 18161 b

A BILL FOR

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Insurance Code is amended by
5 adding Section 356z.43 as follows:

6 (215 ILCS 5/356z.43 new)

7 Sec. 356z.43. Biomarker testing; advanced or metastatic
8 stage 3 or 4 cancer.

9 (a) As used in this Section, "biomarker testing" means
10 diagnostic testing of the cancer patient's biospecimen, such
11 as tissue, blood, or other bodily fluids, for DNA or RNA
12 alterations to identify an individual with a subtype of cancer
13 in order to guide patient treatment.

14 (b) An individual or group health care service plan
15 contract that is issued, amended, delivered, or renewed on or
16 after January 1, 2022 shall not require prior authorization
17 for biomarker testing for an insured with advanced or
18 metastatic stage 3 or 4 cancer, nor shall prior authorization
19 be required for biomarker testing of cancer progression or
20 recurrence in the insured with advanced or metastatic stage 3
21 or 4 cancer.